A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Here’s what the state found in study of Staten Island cancer rateson October 18, 2019 at 3:07 am
The literature also shows that screening events and overuse of diagnostic imaging can increase local thyroid cancer rates because they identify insignificant cancers where active treatment is not the ...
- Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Canceron October 18, 2019 at 12:37 am
The Prescription Drug User Fee Act (PDUFA) date for [fam-] trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive ...
- Innovative Cancer Treatment Medical Device Company Appoints Dr. Jonathan Jarow, MD as Chief Medical Officeron October 17, 2019 at 5:47 pm
Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of patients with prostate, ...
- Recent Research Utilizing AI For Early Detection Of Breast Cancer Has Doctors Rethinking The Human Role In Diagnosison October 17, 2019 at 5:22 pm
Breast cancer is the main source of cancer-related deaths among women, and unfortuneately is very hard to detect. About one of every 10 cancers are misdiagnosed as not cancerous, meaning that a ...
- Expert Panel: Cancer Treatment Plans Should Include Tailored Exercise Prescriptionson October 17, 2019 at 10:18 am
View and download the Exercise for Cancer Prevention and Treatment infographic. To implement the recommendation for translating evidence into practice, ACSM and its Exercise is Medicine (EIM) ...
- Cancer survivors square off in the boxing ring to help find a cureon October 17, 2019 at 6:37 am
The group's founders met at the gym. Co-founder, Julie Anne Kelly, who is a cancer survivor, said she started boxing after treatment. "After treatment, I kind of fell into a little bit of a depression ...
- UPDATE 1-AstraZeneca breast cancer treatment gets FDA priority reviewon October 17, 2019 at 12:29 am
Oct 17 (Reuters) - AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct ...
- FDA: Deliveries Of Scarce Childhood Cancer Drug Due To Resume Later In October, But Shortages May Continue For Monthson October 16, 2019 at 11:24 pm
Proposals that could be enacted in a reasonable time frame for today’s children that merit consideration include but are not limited to (1) establishment and maintenance of a national stockpile of key ...
- Lilly's pancreatic cancer treatment fails late-stage studyon October 16, 2019 at 4:21 am
(Reuters) - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study. The trial ...
via Bing News